PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
AetnaCommercial · Coverage · Medical Policy · Pain Management, Neurology, OncologyMedium impact

Ziconotide (Prialt) (CPB 0712, reviewed 2026-03-11)

Effective date
Not stated in the notice
Identified
Aug 19, 2026

Summary

Intrathecal ziconotide (Prialt) is considered medically necessary for members with severe chronic pain that is intolerant of or refractory to other treatments, such as systemic analgesics, adjunctive therapies, or intrathecal morphine. It is considered not medically necessary for members with a pre-existing history of psychosis, an infection at the micro-infusion injection site, uncontrolled bleeding diathesis, or spinal canal obstruction. Use for autism, epilepsy, Irukandji syndrome, migraines, primary lateral sclerosis, and stroke is considered experimental, investigational, or unproven, as is the intrathecal combination of ziconotide, morphine, and levobupivacaine for cancer-related refractory pain.

Get alerts when payers change rules like this one

We check Aetna and other payers every day and email you when a change matches your specialty and state.

Get Aetna alertsPolicy Monitoring is free. No card required.

What to do

Action · 7 steps
01Claims for ziconotide (J2278, 1 mcg) need documentation that the member has severe chronic pain that is intolerant of or refractory to other treatments, such as systemic analgesics, adjunctive therapies, or intrathecal morphine.
02The policy lists ICD-10 codes G89.0 through G89.4 (pain, not elsewhere classified) as covered when the selection criteria are met.
03Ziconotide is not medically necessary for members with a pre-existing history of psychosis, or where there is an infection at the micro-infusion injection site, uncontrolled bleeding diathesis, or spinal canal obstruction.
04The policy lists these ICD-10 codes as not covered: C72.0 (spinal canal obstruction), D33.4 (spinal canal obstruction), D69.9 (uncontrolled bleeding diathesis), F23, F24, F28, F29 (psychosis), F84.0 (autism), G12.23 (primary lateral sclerosis), G89.3 (neoplasm related pain), and Z86.59 (pre-existing history of psychosis).
05Pump codes listed in the policy are E0779, E0780, E0781, E0783, E0785, and E0786.
06C9811 must be a qualifying Medicare non-opioid medical device for post-surgical pain relief in accordance with section 4135 of the CAA, 2023.
07Morphine codes J2270, J2272, and S0093 are listed as related codes.

Codes mentioned

J2278C9811E0779E0780E0781E0783E0785E0786J2270J2272S0093C72.0D33.4D69.9F23F24F28F29F84.0G12.23Z86.59G89.3

Original notice

Ziconotide (Prialt) (CPB 0712, reviewed 2026-03-11)
aetna.com · Always check the source before changing claims.
View original ↗

Related policy hubs

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account